How does ponatinib act on cancer cells?

Ponatinib, as a polytyrosine kinase inhibitor, plays an important role in the treatment of chronic myelogenous leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and other malignant tumors. It blocks the growth and spread of cancer cells by blocking and interfering with the activity of many tyrosine kinase proteins, thereby helping to shrink the cancer or prevent it from getting worse.

Tyrosine kinases play a key role in cell signaling, and they are responsible for regulating cell growth, proliferation, differentiation, and apoptosis. However, in cancer cells, tyrosine kinases are often abnormally active, leading to abnormal proliferation and invasion of cancer cells. Ponatinib targets this mechanism by precisely inhibiting multiple tyrosine kinases to block the growth signaling pathways of cancer cells.

Ponatinib can specifically bind to the active site of target tyrosine kinases, thereby preventing them from catalyzing the transfer of phosphate groups on ATP to tyrosine residues on proteins, thereby inhibiting the function and activity of these proteins. This process effectively blocks the signaling that cancer cells need to grow and spread, making it impossible for cancer cells to continue to proliferate.

In addition, ponatinib also has anti-angiogenic effects. By inhibiting tyrosine kinases associated with angiogenesis, ponatinib prevents cancer cells from getting enough oxygen and nutrients, further inhibiting the growth and spread of cancer cells.

The effect of ponatinib is not limited to inhibiting the activity of tyrosine kinases, it can also induce cancer cells to enter the apoptosis program. Apoptosis is a programmed cell death process through which cancer cells can actively self-destruct, thereby reducing the number of tumor cells. Ponatinib can further exert its anti-tumor effect by inducing apoptosis in cancer cells.

In summary, ponatinib blocks the growth signaling pathways of cancer cells by precisely inhibiting multiple tyrosine kinases, while inhibiting angiogenesis and inducing apoptosis of cancer cells, thus helping to shrink cancer or prevent its further growth and spread, providing new treatment options and hope for patients with malignant tumors.

xa0

Reference link: https://www.cancerresearchuk.org/about-cancer/treatment/drugs/ponatinib